Healio Minute Podcast, Gastroenterology Edition: Top Headlines - Week of November 21, 2022
Click Here to Manage Email Alerts
In this edition, best practice statements for celiac disease; older patients with IBD at risk for treatment failure with vedolizumab; Follow-up surveillance for post-colonoscopy CRC and more.
Read the full coverage here:
AGA releases 10 best practice statements for management of refractory celiac disease
Older patients with IBD at higher risk for treatment failure with vedolizumab
Follow-up surveillance within 5 years may detect post-colonoscopy CRC
Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks
PLX065 reduces liver fat content, prevents worsening of fibrosis in NASH
References:
Degasperi E, et al. Extension of bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the Italian multicenter study (HEP4Di). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid).
Green PHR, et al. Gastroenterology. 2022;doi:10.1053/j.gastro.2022.07.086
Harrison SA, et al. PLX065 (deuterium-stabilized r-enantiomer of pioglitazone) reduces liver fat content and improves liver histology without PPAR gamma-mediated side effects in patients with NASH: Analysis of a 36-week placebo-controlled phase 2 trial (DESTINY1). Presented at: The Liver Meeting; Nov. 4-8, 2022; Washington (hybrid meeting).
Imperiale TF, et al. Abstract S245: Risk factors for 5-year post-colonoscopy colorectal cancers
(PCCRCs). Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).
Singh S, et al. JAMA Netw Open. 2022;doi: 10.1001/jamanetworkopen.2022.34200.
Collapse
Read more about
Click Here to Manage Email Alerts
